“A million dollars isn’t cool. You know what is? A billion dollar valuation.”

That’s what the fictionalized Sean Parker told Mark Zuckerberg in the 2010 movie “The Social Network,” depicting Facebook’s early days and a founder seeking unicorn startup status.

That tech sentiment has caught on with drugmakers looking to scale up the definition of a blockbuster beyond the $1 billion in annual revenue benchmark. What’s better than a blockbuster drug? A megablockbuster. 

The number of drugs that reached at least $10 billion in annual revenue hit a new high last year, thanks in part to the rapid popularity of GLP-1 weight loss and diabetes meds. Today, we’re exploring how drugmakers are seeking megablockbusters, from long-haul holdouts to newly arrived juggernauts.

Thanks for reading.